ADMA Biologics, Inc.

How big is ADMA Biologics, Inc.?

As of Jun 18, ADMA Biologics, Inc. has a market capitalization of $4.51 billion, with net sales of $459.38 million and net profit of $206.77 million over the latest four quarters. Shareholder's funds are $349.02 million and total assets are $498.38 million.

As of Jun 18, ADMA Biologics, Inc. has a market capitalization of 4,509.69 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 459.38 million, while the sum of Net Profit for the same period is 206.77 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 349.02 million and Total Assets at 498.38 million.

What does ADMA Biologics, Inc. do?

ADMA Biologics, Inc. is a late-stage biopharmaceutical company focused on developing and marketing specialty plasma-based biologics for infectious diseases. As of March 2025, it reported net sales of $115 million and a net profit of $27 million, with a market cap of approximately $4.51 billion.

Overview: <BR>ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Net Sales: 115 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 27 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4,509.69 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.01 <BR>Return on Equity: 55.71% <BR>Price to Book: 12.08<BR><BR>Contact Details: <BR>Address: C/O Adma Biologics, Inc., 465 State Route 17 RAMSEY NJ : 07446 <BR>Tel: 1 201 4785552 <BR>Fax: 1 201 4785553 <BR>Website: https://www.admabiologics.com/

Who are in the management team of ADMA Biologics, Inc.?

As of March 2022, the management team of ADMA Biologics, Inc. includes Mr. Steven Elms (Independent Chairman), Mr. Adam Grossman (President and CEO), Dr. Jerrold Grossman (Vice Chairman), and independent directors Ms. Martha Demski, Mr. Bryant Fong, and Mr. Lawrence Guiheen.

As of March 2022, the management team of ADMA Biologics, Inc. includes the following individuals:<BR><BR>- Mr. Steven Elms: Independent Chairman of the Board<BR>- Mr. Adam Grossman: President, Chief Executive Officer, Co-Founder, Director<BR>- Dr. Jerrold Grossman: Vice Chairman of the Board, Co-Founder<BR>- Ms. Martha Demski: Independent Director<BR>- Mr. Bryant Fong: Independent Director<BR>- Mr. Lawrence Guiheen: Independent Director<BR><BR>This team comprises a mix of leadership roles, including executive positions and independent directors.

Should I buy, sell or hold ADMA Biologics, Inc.?

Is ADMA Biologics, Inc. technically bullish or bearish?

As of September 8, 2025, ADMA Biologics, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD and KST, despite a bullish weekly RSI, and has underperformed the S&P 500 with year-to-date and one-year returns of -5.77% and -16.36%, respectively.

As of 8 September 2025, the technical trend for ADMA Biologics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the weekly MACD and KST both being bearish, and daily moving averages also reflecting a bearish trend. The weekly RSI is bullish, but the overall sentiment is dampened by the mildly bearish signals from Bollinger Bands and OBV. <BR><BR>In terms of performance, ADMA has underperformed the S&P 500 across multiple periods, with a year-to-date return of -5.77% compared to the S&P 500's 12.22%, and a one-year return of -16.36% versus 17.14%.

Is ADMA Biologics, Inc. overvalued or undervalued?

As of October 17, 2025, ADMA Biologics, Inc. is fairly valued with a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78, outperforming some peers like Protagonist Therapeutics, Inc., despite a year-to-date return of -16.27% compared to the S&P 500's 13.30%, while achieving a remarkable 3-year return of 433.83%.

As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78, which suggest a balanced valuation relative to its earnings and assets.<BR><BR>In comparison to its peers, ADMA Biologics, Inc. has a P/E ratio of 18.56, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.18. This indicates that ADMA is positioned more favorably in terms of valuation compared to some competitors. Notably, while ADMA's stock has underperformed against the S&P 500 in the short term, with a year-to-date return of -16.27% compared to the S&P 500's 13.30%, it has significantly outperformed over longer periods, with a 3-year return of 433.83% versus 81.19% for the index.